Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock Has Consensus Target Price of $367.20 According to Analysts

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has earned a consensus recommendation of “Moderate Buy” from the twenty-three brokerages that are presently covering the company, Marketbeat reports. Five analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $367.20.

A number of brokerages recently issued reports on ALNY. Raymond James Financial raised shares of Alnylam Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $420.00 price objective for the company in a report on Monday, August 3rd. TD Cowen reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, August 31st. Wells Fargo & Company cut their price target on shares of Alnylam Pharmaceuticals from $316.00 to $256.00 and set an “equal weight” rating for the company in a report on Friday, August 14th. Wall Street Zen cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 2nd. Finally, Barclays lowered their price objective on Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating for the company in a research report on Monday, August 3rd.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $249.59 on Tuesday. Alnylam Pharmaceuticals has a 1 year low of $197.81 and a 1 year high of $495.55. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99. The firm has a market capitalization of $33.40 billion, a PE ratio of 46.39 and a beta of 0.31. The business has a 50 day simple moving average of $244.49 and a 200-day simple moving average of $283.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The company had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.32 billion. During the same quarter in the previous year, the company posted ($0.51) earnings per share. The firm’s revenue for the quarter was up 66.9% compared to the same quarter last year. Equities research analysts anticipate that Alnylam Pharmaceuticals will post 6.71 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. QRG Capital Management Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 16.5% in the 2nd quarter. QRG Capital Management Inc. now owns 2,652 shares of the biopharmaceutical company’s stock worth $798,000 after acquiring an additional 375 shares during the last quarter. Anchor Investment Management LLC increased its holdings in Alnylam Pharmaceuticals by 20.2% in the 2nd quarter. Anchor Investment Management LLC now owns 3,389 shares of the biopharmaceutical company’s stock valued at $1,020,000 after purchasing an additional 570 shares during the last quarter. National Pension Service raised its position in Alnylam Pharmaceuticals by 7.9% in the second quarter. National Pension Service now owns 198,295 shares of the biopharmaceutical company’s stock valued at $59,693,000 after purchasing an additional 14,506 shares during the period. WINTON GROUP Ltd acquired a new position in Alnylam Pharmaceuticals during the second quarter worth $2,372,000. Finally, Engineers Gate Manager LP boosted its position in shares of Alnylam Pharmaceuticals by 3.0% during the second quarter. Engineers Gate Manager LP now owns 33,469 shares of the biopharmaceutical company’s stock worth $10,075,000 after buying an additional 967 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi) technology. RNAi therapies are designed to silence specific genes involved in disease, offering a way to target conditions that may be difficult to treat with conventional drug approaches. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam’s commercial products include Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Amvuttra (vutrisiran).